Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.

Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Abstract Text:

Li Ma,Julie Teruya-Feldstein,Pauline Bonner,Rosa Bernardi,David Neal Franz,David Witte,Carlos Cordon-Cardo,Pier Paolo Pandolfi,

Constitutive activation of extracellular signal-regulated kinases (Erk1/2) is frequently implicated in human cancers. Recently, aberrantly activated Erk was also found in brain lesions associated with tuberous sclerosis (TSC). We reported previously that Erk might contribute to tumorigenesis by phosphorylating TSC2 at specific residues, particularly S664. In our present study, 25 TSC-related cortical tubers or subependymal giant cell astrocytomas, as well as tissue microarrays of six types of human cancers, were analyzed for the expression of phospho-Erk (pErk) 1/2, S664-phospho-TSC2 (pTSC2), and phospho-S6 (pS6) by immunohistochemistry. We found that Erk-mediated TSC2 phosphorylation occurred at a high incidence and positively correlated with mitogen-activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR) activation in TSC-associated brain lesions as well as in various cancers. Interestingly, in certain types of cancers (e.g., breast carcinoma and colon carcinoma), S664-pTSC2 seemed to be a more sensitive marker than pErk. Furthermore, most of the pTSC2-positive samples ( approximately 75%) were positive for pS6, but only 40% to 55% of the pS6-positive tumors exhibited TSC2 phosphorylation. Our results show that S664 TSC2 phosphorylation is a marker for Erk-mediated (as opposed to Akt-mediated) mTOR activation in TSC and human cancer. On the basis of these findings, TSC2 phosphorylation at S664 can be used to identify patients that may benefit from antitumor therapy with MAPK and mTOR inhibitors. Importantly, our results indicate that Erk-mediated phosphorylation and inactivation of TSC2 can be critical in development of hamartomatous lesions in TSC and cancer pathogenesis.

Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Publishing Authors By Initials

L Ma,J Teruya-Feldstein,P Bonner,R Bernardi,DN Franz,D Witte,C Cordon-Cardo,PP Pandolfi,

For similar proteins: neoplasm proteins: tumor suppressor proteins research abstracts see: proteins: neoplasm proteins: tumor suppressor proteins research

PUBMED ID PMID:

MEDLINE DATE:

Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Cancer research

VOLUME: 67

Page Numbers: 7106-12

Journal Abbreviation: Cancer Res.

ISSN: 0008-5472

DAY: 1

MONTH: Aug

YEAR: 2007

Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2984705

Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Keywords Mesh Terms:

KEYWORDS: Tumor Suppressor Proteins

MESH TERMS: metabolism

Chemical & Substance for Abstract: Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Information

Substance Name: Protein Kinases

Registry Number: EC 2.7.1.37

Grant and Affiliation Information for Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.

AFFILIATION: Cancer Biology and Genetics Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

Country: United States

AGENCY: United States NCI

GRANT: CA84292

ACRONYM: CA

MEDLINETA: Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer Related Publications

• Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events.
• Abnormal synthesis of IgA in coeliac disease and related disorders.
• Active thymopoiesis in idiopathic chronic pancreatitis.
• Activity of a hydroxybibenzyl bryophyte constituent against Leishmania spp. and Trypanosoma cruzi: In silico, in vitro and in vivo activity studies.
• CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor.
• Corneal diameter in premature infants.
• Cyclin-dependent kinase antagonizes promyelocytic leukemia zinc-finger through phosphorylation.
• Early dose response analysis of ocular hypotensive effects of propranolol in patients with ocular hypertension.
• Effect of topical atenolol on intraocular pressure.
• Factor structure evaluation of the childhood autism rating scale.
• HCV co-infection does not affect the TREC/IL-7 pathway in HIV disease.
• Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
• Hopping hotspots: global shifts in marine biodiversity.
• Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.
• Identification of jejunal interference in pancreatic scanning by combined photoscintigraphic and X-rays studies.
• Initiation of mRNA translation in oncogenesis: the role of eIF4E.
• Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse.
• Origin of urinary fibrin/fibrinogen degradation products in glomerulonephritis.
• PML targeting eradicates quiescent leukaemia-initiating cells.
• Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF.
• SnapShot: PTEN signaling pathways.
• Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies.
• Tenets of PTEN tumor suppression.
• The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence.
• The promyelocytic leukaemia protein tumour suppressor functions as a transcriptional regulator of p63.
• The theory of APL revisited.
• Thrombosis and oral contraceptives: possible predisposition.
• Topical atenolol versus pilocarpine: a double-blind study of the effect on ocular tension.
• [Produced urobilinuria; preliminary observations and considerations.]
• [Reduced NO bioavailability in chronic renal failure: a new progression factor?]